Slides
Page 1
Investor Presentation November 3, 2026 Anthem Biosciences Limited
Page 2
Safe Harbour Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute “forward-looking statements”. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.
Page 3
Consolidated Profit & Loss Statement: Q2FY27 vs Q2FY26 vs Q1FY27 Performance 3 Particulars (₹ Mn) Q2FY27 Q2FY26 YoY Q1FY27 QoQ FY26 Revenue from Operations 5,940 5,505 7.9% 4,182 42.0% 21,293 CRDMO 5,093 4,662 9.2% 3,408 49.4% 17,775 Specialty Ingredients 848 843 0.6% 774 9.5% 3,518 Other Income 589 478 23.3% 249 136.6% 1,508 Total Revenues 6,529 5,983 9.1% 4,431 47.4% 22,801 Cost of materials consumed and changes in inventories 1,847 2,234 -17.3% 1,462 26.3% 8,123 Employee benefits expense 813 672 20.9% 788 3.1% 2,812 Other expenses 566 415 36.2% 426 32.8% 1,969 EBITDA 3,304 2,661 24.1% 1,755 88.3% 9,896 EBITDA Margins 50.6% 44.5% 610 bps 39.6% 1,100 bps 43.4% Finance cost 33 31 8.3% 9 273.0% 71 Depreciation and amortization expense 307 335 -8.3% 300 2.4% 1,341 Profit before tax 2,964 2,296 29.1% 1,446 105.0% 8,486 Total tax expense 849 562 51.2% 246 244.6% 2,324 Profit after tax 2,115 1,734 21.9% 1,199 76.3% 5,917
Page 4
Q2FY27 Consolidated Financial Highlights 4 5,505 5,940 Q2FY26 Q2FY27 Revenues (₹ Mn) 2,661 3,304 Q2FY26 Q2FY27 EBITDA1 (₹ Mn) and EBITDA Margins (%age) 1,734 2,115 Q2FY26 Q2FY27 PAT (₹ Mn) and PAT Margins (%age) 44.5% 50.6% 29.0% 32.4% 0.0% 10.0% 20.0% 30.0% 40.0% 17,197 15,380 June 30, 2026 Sept 30, 2026 Net Cash (₹ Mn) CRDMO 85.7% Specialty Ingredients 14.3% Q2FY27 Revenue Split 2,296 2,964 Q2FY26 Q2FY27 PBT (₹ Mn) and PBT Margins (%age) 38.4% 45.4% Note: 1. EBITDA for Q2FY27 includes Other Income of INR 588.98 Mn (Other Operating Income o/a of forex gain (net) 57.54 Mn and Financial / Non Operating Income of INR 531.45 Mn). Corresponding figures for Q2FY26 was Other Income of INR 477.53 Mn (Other Operating Income o/a of forex gain (net) INR 303.40 Mn and Financial / Non Operating Income of INR 174.13 Mn)
Page 5
Growth accelerated in Q2FY27, yielding robust financial performance and highest ever margins 5 Strong Business Performance Robust Technology and Infrastructure Strong Returns and Balance Sheet 26.8%/50.3% ROE / Q2FY27 Post Tax ROCE 1.55x Q2FY27 Gross Fixed Assets Turnover 1.16x Net Cash / Q2FY27 EBITDA* ₹5,940 Mn Q2FY27 Revenues 50.6% Q2FY27 EBITDA Margin 32.4% Q2FY27 PAT Margin 2,344 / 1,173 # Employees / Scientific Staff 425KL Custom Synthesis Capacity 142KL Fermentation Capacity *Based on Annualised EBITDA
Page 6
Consolidated Profit & Loss Statement: H1FY27 vs H1FY26 Performance 6 Particulars (₹ Mn) H1FY27 H1FY26 YoY FY26 Revenue from Operations 10,123 10,914 -7.2% 21,293 CRDMO 8,501 9,195 -7.6% 17,775 Specialty Ingredients 1,622 1,718 -5.6% 3,518 Other Income 838 699 19.9% 1,508 Total Revenues 10,960 11,613 -5.6% 22,801 Cost of materials consumed and changes in inventories 3,309 4,542 -27.2% 8,123 Employee benefits expense 1,601 1,391 15.1% 2,812 Other expenses 992 875 13.4% 1,969 EBITDA 5,059 4,805 5.3% 9,896 EBITDA Margins 46.2% 41.4% 480 bps 43.4% Finance cost 42 47 -11.0% 71 Depreciation and amortization expense 607 599 1.3% 1,341 Profit before tax 4,410 4,159 6.0% 8,486 Total tax expense 1,096 1,066 2.8% 2,324 Profit after tax 3,314 3,092 7.2% 5,917
Page 7
H1FY27 Consolidated Financial Highlights 7 10,914 10,123 H1FY26 H1FY27 Revenues (₹ Mn) 4,805 5,059 H1FY26 H1FY27 EBITDA2 (₹ Mn) and EBITDA Margins (%age) 3,092 3,314 H1FY26 H1FY27 PAT (₹ Mn) and PAT Margins (%age) 41.4% 46.2% 26.6% 30.2% 0.0% 9,931 15,380 Sept 30, 2025 Sept 30, 2026 Net Cash (₹ Mn) CRDMO 84.0% Specialty Ingredients 16.0% H1FY27 Revenue Split 4,159 4,410 H1FY26 H1FY27 PBT (₹ Mn) and PBT Margins (%age) 35.8% 40.2% 0.0%10.0%20.0%30.0%40.0% Note: 2. EBITDA for H1FY27 includes Other Income of INR 837.87 Mn (Other Operating Income o/a of forex gain (net) 70.22 Mn and Financial / Non Operating Income of INR 767.65 Mn). Corresponding figures for H1FY26 was Other Income of INR 699.08 Mn (Other Operating Income o/a of forex gain (net) INR 340.39 Mn and Financial / Non Operating Income of INR 358.69 Mn)
Page 8
Financial performance continues to remain strong with robust return profile for H1FY27 8 Strong Business Performance Platforms across discovery to commercialization Strong Returns and Balance Sheet 21.0% / 39.3% ROE / H1FY27 Post Tax ROCE 1.32x H1FY27 Gross Fixed Assets Turnover 1.52x Net Cash / H1FY27 EBITDA* ₹10,123 Mn H1FY27 Revenues 46.2% H1FY27 EBITDA Margin 30.2% H1FY27 PAT Margin 65.3% Commercial Molecules Contribution to Revenues 15 + 9 Commercial + Late Stage (Phase III) Molecules 8.1% R&D Services Contribution to Revenues *Based on Annualised EBITDA
Page 9
Financial Highlights: Q2FY27 and H1FY27 9 Quarterly Performance: Consolidated Revenue from Operations was ₹5,940 Mn for the quarter CRDMO business delivered ₹5,093 Mn revenues Specialty Ingredients delivered ₹848 Mn revenues EBITDA was ₹3,304 Mn, with EBITDA margins at 50.6% PAT (Profit After Tax) was ₹2,115 Mn, with PAT margins at 32.4% Half Year Performance: Consolidated Revenue from Operations was ₹10,123 Mn for the half year CRDMO business delivered ₹8,501 Mn revenues Specialty Ingredients delivered ₹1,622 Mn revenues EBITDA was ₹5,059 Mn, with EBITDA margins at 46.2% PAT (Profit After Tax) was ₹3,314 Mn, with PAT margins at 30.2% Net Cash position as of Sept 30, 2026, is ₹15,380 Mn
Page 10
Message from Chairman, MD and CEO 10 AJAY BHARDWAJ Chairman, MD & CEO “We are pleased to report a robust performance for Q2FY27, driven by our CRDMO revenue stream. Underlying demand continues to remains strong and we are confident in our ability to sustain growth and create long-term value for all stakeholders We expanded our EBITDA and PAT margins year-on-year. By maintaining strict discipline around cost efficiencies, yield optimization, and workforce productivity, we have further solidified our industry-leading margins, and are well-positioned to sustain this performance all year”.
Page 11
Unit I: No.49, F1 &F2, Canara Bank Road, Bommasandra Industrial Area Phase 1, Bommasandra, Bangalore, 560 099, India Unit II: Plot No 276-P & 277-P , SurveyNo-20, Harohalli Industrial Area, Phase II, Near Bannikuppe Village, Kanakapura Taluk,Ramnagar District, Harohalli, Karnataka 562112, India Anthem Biosciences Limited NeoAnthem Lifesciences Private Limited Unit III: 313-P ,314-P,318-P,Harohalli Industrial Area, Phase II, Kanakapura Taluk,Ramnagar District, Harohalli, Karnataka, 562112, India Thank You For further information please contact investors.abl@anthembio.com or anthem@adfactorspr.com